These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11136388)

  • 21. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
    Roberts HR
    Vox Sang; 1999; 77 Suppl 1():38-41. PubMed ID: 10529686
    [No Abstract]   [Full Text] [Related]  

  • 22. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.
    Gringeri A; Fischer K; Karafoulidou A; Klamroth R; López-Fernández MF; Mancuso E;
    Haemophilia; 2011 Jul; 17(4):630-5. PubMed ID: 21323801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey.
    Franchini M; Coppola A; Rocino A; Zanon E; Morfini M; ; Accorsi A; Aru AB; Biasoli C; Cantori I; Castaman G; Cesaro S; Ciabatta C; De Cristofaro R; Delios G; Di Minno G; D'Incà M; Dragani A; Ettorre CP; Gagliano F; Gamba G; Gandini G; Giordano P; Giuffrida G; Gresele P; Latella C; Luciani M; Margaglione M; Marietta M; Mazzucconi MG; Messina M; Molinari AC; Notarangelo LD; Oliovecchio E; Peyvandi F; Piseddu G; Rossetti G; Rossi V; Santagostino E; Schiavoni M; Schinco P; Serino ML; Tagliaferri A; Testa S
    Haemophilia; 2014 Mar; 20(2):e128-35. PubMed ID: 24533954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations.
    Teitel JM
    Haemophilia; 1999 Sep; 5 Suppl 3():43-9. PubMed ID: 10597387
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany.
    Auerswald G; von Depka Prondzinski M; Ehlken B; Kreuz W; Kurnik K; Lenk H; Scharrer I; Schramm W; Zimmermann R
    Haemophilia; 2004 Sep; 10(5):499-508. PubMed ID: 15357777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The hope and reality of long-acting hemophilia products.
    Pipe SW
    Am J Hematol; 2012 May; 87 Suppl 1():S33-9. PubMed ID: 22389200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The future of plasma-derived clotting factor concentrates.
    Hoots WK
    Haemophilia; 2001 Jan; 7 Suppl 1():4-9. PubMed ID: 11240612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
    Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
    Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.
    Berntorp E
    Haemophilia; 2009 Jan; 15(1):3-10. PubMed ID: 19016901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
    Caviglia H; Candela M; Galatro G; Neme D; Moretti N; Bianco RP
    Haemophilia; 2011 Nov; 17(6):910-9. PubMed ID: 21342367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Some recent developments regarding arthropathy and inhibitors in haemophilia.
    Rodriguez-Merchan EC
    Haemophilia; 2008 Mar; 14(2):242-7. PubMed ID: 18201189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates.
    Giangrande P; Seitz R; Behr-Gross ME; Berger K; Hilger A; Klein H; Schramm W; Mannucci PM
    Haemophilia; 2014 May; 20(3):322-5. PubMed ID: 24731129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Choice of replacement therapy for hemophilia-a rebuttal.
    Giangrande PL
    J Thromb Haemost; 2003 Dec; 1(12):2698-9; author reply 2699-700. PubMed ID: 14675118
    [No Abstract]   [Full Text] [Related]  

  • 34. Treating haemophilia A with recombinant blood factors: a comparison.
    Ananyeva N; Khrenov A; Darr F; Summers R; Sarafanov A; Saenko E
    Expert Opin Pharmacother; 2004 May; 5(5):1061-70. PubMed ID: 15155108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of factor VIII inhibitors.
    Acharya SS; DiMichele DM
    Best Pract Res Clin Haematol; 2006; 19(1):51-66. PubMed ID: 16377541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylaxis in haemophilia with inhibitors: update from international experience.
    Carcao M; Lambert T
    Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Promising coagulation factor VIII bypassing strategies for patients with haemophilia A.
    Duan X; Tang M; Zhang J; Yu H; Xu R
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):539-52. PubMed ID: 24614429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of novel treatment options for patients with haemophilia.
    Ehrlich HJ; Wong WY; Ewenstein BM; Dockal M; Turecek PL; Gringeri A; Chehadeh H; Löw-Baselli A; Scheiflinger F; Reininger AJ
    Hamostaseologie; 2013; 33 Suppl 1():S36-8. PubMed ID: 24169902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On the treatment of hemorrhage in patients with hemophilia and associated inhibitors.
    Tarantino M; Aledort L
    Transfusion; 2001 Dec; 41(12):1628-9. PubMed ID: 11778084
    [No Abstract]   [Full Text] [Related]  

  • 40. The improved factor concentrate.
    Lillicrap D
    Hamostaseologie; 2009 Jan; 29(1):71-3. PubMed ID: 19151851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.